Agilent Guides Q4 Adjusted EPS to $1.71-$1.74, Above Consensus
A sits 43% above its 52-week low of $108.35.
Summary
Agilent issued Q4 adjusted EPS guidance of $1.71-$1.74, a range that appears to exceed current consensus expectations. The company is trading near its 52-week high, and this forward-looking estimate provides a concrete earnings target for the upcoming quarter. The guidance follows a strong Q2 2026 report and recent positive developments, including FDA expanded approval for its PD-L1 test and a completed Biocare Medical acquisition. Traders will likely view this as a sign of continued momentum, though the market's reaction will depend on how the range compares to the exact consensus figure.
At the time of this announcement, A was trading at $155.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $43.7B. The 52-week trading range was $108.35 to $160.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.